HealthyNCT06043089
Impact of Beetroot Supplementation in Athletes
A study of Healthy, run by University School of Physical Education, Krakow, Poland at 1 site in Poland.
Trial summary
Several previous studies observed a positive effect of beetroot supplementation on sports performance in athletes, mainly in endurance performance. However, less attention has been paid to its effects on short-duration performance, especially in youth athletes. Read more about this study
- Who is it for?
- Ages 14 to 23 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 sitePoland
- Study dates
- 23 Aug 2023to 16 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 23 years
- Men only
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- male
- good general health assessed by physician
- highly trained
- written consent to participate
Who cannot join
- medication or dietary supplements used within the previous month, which could potentially impact the study outcomes
- history of sleep nor neurological disorders
- chronic use (6 months) of any antibacterial mouthwash products.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Beetroot Supplementation on Sports Performance, Prooxidant-antioxidant Balance and Sleep in Athletes
Several previous studies observed a positive effect of beetroot supplementation on sports performance in athletes, mainly in endurance performance. However, less attention has been paid to its effects on short-duration performance, especially in youth athletes. Moreover, only a few previous investigations performed biochemical analyses, including pro-oxidant balance assessments. It is especially important because chronic nitrate intake might directly cause the production of reactive nitrogen species and reactive oxygen species in other subcellular compartments, leading to more oxidative stress. Additionally, no previous study verified the impact of beetroot intake on sleep.
- Conditions
- Healthy
- Being tested
- Beetroot juice supplementation or placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beetroot juice supplementation or placeboDietary supplement
Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
| Study group | Role | What they receive |
|---|---|---|
| Placebo group | Placebo comparator | Athletes received 7 days of placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content). Receives: Dietary Supplement: Beetroot juice supplementation or placebo |
| Beetroot group | Experimental | Athletes received 7 days of beetroot juice (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK). Receives: Dietary Supplement: Beetroot juice supplementation or placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Performance test
yo-yo intermittent recovery test level 1
Measured: 7 days after treatment
Changes in nitrates
Blood plasma will be obtained to measure nitrate concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in nitrites
Blood plasma will be obtained to measure nitrite concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in prooxidant status
Blood plasma will be obtained to measure total oxidative status
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in antioxidant status
Blood plasma will be obtained to measure total antioxidant capacity
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in oxidative stress index
The oxidative stress index will be calculated as the ratio of plasma prooxidant to antioxidant status
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in nitrooxidative stress markers
Blood plasma will be obtained to measure 3-nitrotyrosine concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in protein oxidation
Blood plasma will be obtained to measure advanced protein oxidation products concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in nucleic acid oxidation
Blood plasma will be obtained to measure ox-8-hydroxy-2'-deoxyguanosine (8-OHdG) concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in lipids oxidation
Blood plasma will be obtained to measure thiobarbituric acid reactive substances concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in exercise-induced metabolic acidosis
Arterialized blood will be obtained to measure lactate concentration
Measured: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Objective Sleep - Time in bed
Total time spent in bed during the night assessed by sleep radar
Measured: nights 1 - 7 during treatment
Objective Sleep - Sleep-onset latency
The time it takes from when the athlete intends to go to sleep and actually starts to sleep assessed by sleep radar
Measured: nights 1 - 7 during treatment
Objective Sleep - Total sleep time
Total sleep time obtained from sleep onset to time at wake-up assessed by sleep radar
Measured: nights 1 - 7 during treatment
Objective Sleep - Light sleep
Total amount of time in light sleep assessed by sleep radar
Measured: nights 1 - 7 during treatment
Objective Sleep - Deep sleep
Total amount of time in deep sleep assessed by sleep radar
Measured: nights 1 - 7 during treatment
Objective Sleep - REM sleep
Total amount of time in REM sleep assessed by sleep radar
Measured: nights 1 - 7 during treatment
Objective Sleep - Sleep efficiency
The percentage of total sleep time to lights off and leaving bed assessed by sleep radar
Measured: nights 1 - 7 during treatment
Secondary outcomes (17)
Countermovement jump height
Measured: 7 days after treatment
Ball speed velocity
Measured: 7 days after treatment
Sprint test (0-20m)
Measured: 7 days after treatment
Agility T-test
Measured: 7 days after treatment
Maximal isometric handgrip strength
Measured: 7 days after treatment
Flanker task
Measured: 7 days after treatment
Changes in muscle damage markers
Blood serum will be obtained to measure myoglobin concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in muscle enzymes activity
Blood serum will be obtained to measure creatine kinase activity
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in inflammation markers
Blood serum will be obtained to measure C-reactive protein concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in blood count
Whole blood will be obtained to measure leukocyte count
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in anabolic hormones
Blood serum will be obtained to measure testosterone concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in catabolic hormones
Blood serum will be obtained to measure cortisol concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in kidney function markers
Blood serum will be obtained to measure creatinine concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in the purine metabolism marker
Blood serum will be obtained to measure uric acid concentration
Measured: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in hemoglobin concentration
Arterialized blood will be obtained to measure hemoglobin concentration
Measured: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Changes in hematocrit
Arterialized blood will be obtained to measure hematocrit
Measured: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Changes in plasma volume
The change in plasma volume will be calculated using the hemoglobin and hematocrit results
Measured: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2023
- Study start23 Aug 2023
- Primary completion16 Oct 2023
- Study completion16 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University School of Physical Education, Krakow, Poland
- Sponsor type
- University, hospital or other
- Collaborators
- University of Bergen
- Responsible party
- Sponsor
- Investigators
- Aleksandra Filip-Stachnik, Phd, Principal investigator, University of Physcial Education in Cracow
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06043089
- Sponsor's protocol ID
- AWF_MSIT
- Status last verified
- Jan 2024
- First submitted
- 5 Sep 2023
- Last updated
- 1 Feb 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Beetroot Supplementation on Sports Performance, Prooxidant-antioxidant Balance and Sleep in Athletes
- ClinicalTrials.gov ID
- NCT06043089
- Acronym / sponsor ID
- AWF_MSIT
- Conditions
- Healthy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University School of Physical Education, Krakow, PolandUniversity, hospital or other
- Collaborators
- University of Bergen
- Study start
- 23 Aug 2023 (actual)
- Primary completion
- 16 Oct 2023 (actual)
- Study completion
- 16 Oct 2023 (actual)
- First posted
- 21 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Several previous studies observed a positive effect of beetroot supplementation on sports performance in athletes, mainly in endurance performance. However, less attention has been paid to its effects on short-duration performance, especially in youth athletes. Moreover, only a few previous investigations performed biochemical analyses, including pro-oxidant balance assessments. It is especially important because chronic nitrate intake might directly cause the production of reactive nitrogen species and reactive oxygen species in other subcellular compartments, leading to more oxidative stress. Additionally, no previous study verified the impact of beetroot intake on sleep.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo group | Placebo comparator | Dietary Supplement: Beetroot juice supplementation or placeboAthletes received 7 days of placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content). |
| Beetroot group | Experimental | Dietary Supplement: Beetroot juice supplementation or placeboAthletes received 7 days of beetroot juice (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK). |
Who may qualify
- Ages
- 14 to 23 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- male
- good general health assessed by physician
- highly trained
- written consent to participate
Key exclusion criteria (3 listed)
- medication or dietary supplements used within the previous month, which could potentially impact the study outcomes
- history of sleep nor neurological disorders
- chronic use (6 months) of any antibacterial mouthwash products.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beetroot juice supplementation or placeboAthletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content). | Dietary supplement | Beetroot group, Placebo group |
Primary outcome
Performance test
Time frame: 7 days after treatment
yo-yo intermittent recovery test level 1
Changes in nitrates
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure nitrate concentration
Changes in nitrites
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure nitrite concentration
Changes in prooxidant status
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure total oxidative status
Changes in antioxidant status
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure total antioxidant capacity
Changes in oxidative stress index
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
The oxidative stress index will be calculated as the ratio of plasma prooxidant to antioxidant status
Changes in nitrooxidative stress markers
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure 3-nitrotyrosine concentration
Changes in protein oxidation
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure advanced protein oxidation products concentration
Changes in nucleic acid oxidation
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure ox-8-hydroxy-2'-deoxyguanosine (8-OHdG) concentration
Changes in lipids oxidation
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Blood plasma will be obtained to measure thiobarbituric acid reactive substances concentration
Changes in exercise-induced metabolic acidosis
Time frame: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Arterialized blood will be obtained to measure lactate concentration
Objective Sleep - Time in bed
Time frame: nights 1 - 7 during treatment
Total time spent in bed during the night assessed by sleep radar
Objective Sleep - Sleep-onset latency
Time frame: nights 1 - 7 during treatment
The time it takes from when the athlete intends to go to sleep and actually starts to sleep assessed by sleep radar
Objective Sleep - Total sleep time
Time frame: nights 1 - 7 during treatment
Total sleep time obtained from sleep onset to time at wake-up assessed by sleep radar
Objective Sleep - Light sleep
Time frame: nights 1 - 7 during treatment
Total amount of time in light sleep assessed by sleep radar
Objective Sleep - Deep sleep
Time frame: nights 1 - 7 during treatment
Total amount of time in deep sleep assessed by sleep radar
Objective Sleep - REM sleep
Time frame: nights 1 - 7 during treatment
Total amount of time in REM sleep assessed by sleep radar
Objective Sleep - Sleep efficiency
Time frame: nights 1 - 7 during treatment
The percentage of total sleep time to lights off and leaving bed assessed by sleep radar
17 secondary outcomes
Countermovement jump height
Time frame: 7 days after treatment
Ball speed velocity
Time frame: 7 days after treatment
Sprint test (0-20m)
Time frame: 7 days after treatment
Agility T-test
Time frame: 7 days after treatment
Maximal isometric handgrip strength
Time frame: 7 days after treatment
Flanker task
Time frame: 7 days after treatment
Changes in muscle damage markers
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in muscle enzymes activity
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in inflammation markers
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in blood count
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in anabolic hormones
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in catabolic hormones
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in kidney function markers
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in the purine metabolism marker
Time frame: 1) baseline - 2) 7th day of treatment - before the supplementation, 3) 7th day of treatment - before the performance test, 4) 7th day of treatment - immediately after the performance test
Changes in hemoglobin concentration
Time frame: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Changes in hematocrit
Time frame: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Changes in plasma volume
Time frame: 1) Before the performance test 2) 3 minutes after the performance test 3) 10 minutes after the performance test 4) 20 minutes after the performance test
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Feb 2024.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aleksandra Filip-Stachnik, Phd principal investigator
University of Physcial Education in Cracow
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Healthy, run by University School of Physical Education, Krakow, Poland at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Performance test (time frame: 7 days after treatment). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2024.